Fabric Genomics

Fabric Genomics

AI-driven genomic analysis for healthcare

About Fabric Genomics

Simplify's Rating
Why Fabric Genomics is rated
B+
Rated B on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

11-50

Company Stage

Series B

Total Funding

$29M

Headquarters

San Francisco, California

Founded

2009

Overview

Fabric Genomics focuses on genomic analysis and reporting, using artificial intelligence to provide insights for hospitals and diagnostic labs. Their main product, Fabric Enterprise, analyzes Next-Generation Sequencing (NGS) data to identify genetic variants linked to diseases, supporting various genomic tests. The company operates on a software-as-a-service (SaaS) model, allowing clients to quickly interpret genomic data, which is essential for timely diagnoses. Fabric Genomics aims to improve patient outcomes and reduce healthcare costs through faster and more accurate genetic testing.

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnerships with DNAnexus and Oxford Nanopore enhance data analysis speed and scalability.
  • Collaboration with PlumCare RWE expands reach in newborn genome screening in Greece.
  • Involvement in Project FIND-OUT supports rapid genetic diagnosis in infants.

What critics are saying

  • Increasing competition from SOPHiA GENETICS SA and PierianDx Inc. may impact market share.
  • Reliance on partnerships could pose risks if collaborations do not meet expectations.
  • Potential regulatory changes in genomic data privacy could increase compliance costs.

What makes Fabric Genomics unique

  • Fabric Genomics uses AI to enhance genomic analysis and clinical decision support.
  • The company offers a SaaS platform for rapid genomic data interpretation.
  • Fabric GEM algorithm enables automated reanalysis of undiagnosed cases over time.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$29M

Below

Industry Average

Funded Over

2 Rounds

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Below Average

Industry standards

$35M
$30M
Patreon
$45M
Linktree
$65M
Substack
$100M
ClickUp

Benefits

Competitive compensation

Health benefits and coverage

PTO

Parental leave

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

0%

2 year growth

5%
Business Wire
Mar 13th, 2024
Fabric Genomics Partners With Intermountain Children’S Health To Enhance Precision Diagnosis Of Infants And Children Using Whole Genome Sequencing From Broad Clinical Labs

OAKLAND, Calif. SALT LAKE CITY--(BUSINESS WIRE)--Fabric Genomics, the leader in artificial intelligence (AI)-powered next generation sequencing interpretation, is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases. This collaboration is a milestone in helping children facing critical health challenges and receiving care in inpatient and outpatient care settings, starting at Intermountain Primary Children’s Hospital in Salt Lake City, a renowned leader in pediatric healthcare and the flagship pediatric hospital for Intermountain Health. The sample-to-report genome service enables healthcare professionals to identify genetic disorders with unprecedented speed and precision and to tailor treatment plans to the unique genetic makeup of each infant. Offered by partners Broad Clinical Labs and Fabric Genomics, the sample-to-report genomic analysis service makes whole genome sequencing (WGS) and diagnosis accessible to healthcare systems who may not currently have genomics infrastructure and expertise in-house

PharmiWeb
Dec 7th, 2023
Plumcare And Fabric Genomics Announce A Strategic Partnership To Integrate The Fabric Ai Platform With Plumcare'S Firststeps(Tm) Newborn Genome Screening Program In Greece

ATHENS, Greece & OAKLAND, Calif.--(BUSINESS WIRE)--#AI--PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece. The goal of FirstSteps, a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years.The FirstSteps program will leverage the power of the Fabric AI platform to offer rapid, accurate clinical genomic variant interpretation for whole genome sequencing (WGS) of screened newborns in Greece. Fabric AI technology for interpretation of the human genome, powered by the Fabric GEM AI algorithm, will be adapted into the FirstSteps clinical support tool, empowering clinicians to provide timely medical intervention for patients with rare genetic diseases in Greece.“The introduction of the Fabric AI platform into the national population health initiative FirstSteps represents an extension of a longstanding partnership between the two companies, and it will help create an ecosystem to enable drug discovery and development for rare diseases,” said Petros Tsipouras, MD, Managing Partner of PlumCare RWE and Scientific Director of FirstSteps.Professor Dimitris Thanos, PhD, Member of the Academy of Athens and Vice Chairman of the Scientific Advisory Board of FirstSteps said, “Bringing the Fabric AI platform to support and speed up our variant interpretation process will enhance the overall performance of the FirstSteps program and help improve the lives of patients with rare genetic diseases in Greece and around the world.”“We are excited to extend our partnership with PlumCare RWE into the new FirstSteps program to bring our genomics AI analysis technology to Greece to support their precision medicine initiative and additionally, to foster an innovation hub in Greece. This partnership will enable us to expand our reach to Europe and improve outcomes for patients,” said Martin Reese, PhD, Co-Founder and CEO of Fabric Genomics.Fabric Genomics is proud to support the innovative PlumCare team to improve screening for babies in Greece by customizing its universal platform to the specific needs required in the national FirstSteps program. This partnership comes on the heels of Fabric Genomics’ previously announced successful partnerships with Rady Children’s Institute for Genomic Medicine and with the Broad Institute of MIT and Harvard offering affordable clinical whole genome analysis in its effort to bring better genomics-based healthcare to all patients.About PlumCare RWEPlumCare RWE is at the forefront of biotechnology and healthcare data, harnessing the power of real-world evidence and multi-omics analysis to provide actionable insights that enhance both population health and individual family well-being. Our commitment to precision medicine is evident through our comprehensive services that include early screening, accurate diagnosis, and timely interventions, all aimed at fostering better health outcomes for families

Diagnostics World News
Nov 29th, 2023
Illumina Partners With Veracyte; Boston Scientific Corporation Acquires Relievant Medsystems; Oxford Nanopore Collaborates With Fabric Genomics

Illumina partners with Veracyte; Boston Scientific Corporation acquires Relievant Medsystems; Oxford Nanopore collaborates with Fabric Genomics.

PR Newswire
Nov 8th, 2023
Combinedbrain Announces The Launch Of Project Find-Out

Project FIND-OUT facilitates early genetic diagnosis in infants 3 – 12 months of age with symptoms of genetic neurodevelopmental disordersBRENTWOOD, Tenn., Nov. 8, 2023 /PRNewswire/ -- COMBINEDBrain, a non-profit organization dedicated to fast-tracking cures for neurodevelopmental disorders, today announced the launch of Project FIND-OUT (Fast Infant Neurodevelopmental Diagnosis via Outpatient Testing), a collaboration among leading non-profit, academic, and industry organizations.Project FIND-OUT provides whole genome sequencing (WGS) to infants who have early symptoms of rare genetic neurodevelopmental disorders. The goals of the study are to expedite diagnosis of rare genetic neurodevelopmental disorders, to generate evidence on the benefits of genetic testing for patients and their families, and to build capacity at a local level for implementation of genetic testing programs. "Curtailing the diagnostic odyssey through broad genetic testing at first signs of symptoms promises to transform the diagnosis and management of children with neurodevelopmental disorders over the next few years," stated Dr. Seth Berger, M.D., Ph.D., a pediatric geneticist at Children's National Hospital. Dr

Genetic Engineering & Biotechnology News
Nov 3rd, 2023
At ASHG, Fabric Genomics Announces Software Deals with Oxford Nanopore, DNAnexus

At ASHG, Fabric Genomics announces software deals with Oxford Nanopore, DNAnexus.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Fabric Genomics right now.

Find jobs on Simplify and start your career today

💡
We update Fabric Genomics's jobs every 8 hours, so check again soon! Browse all jobs →